APREA THERAPEUTICS AB

Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer

Retrieved on: 
Monday, August 5, 2019

BOSTON and STOCKHOLM, Aug. 5, 2019 /PRNewswire/ -- Aprea Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Scott Coiante as Senior Vice President and Chief Financial Officer.

Key Points: 
  • BOSTON and STOCKHOLM, Aug. 5, 2019 /PRNewswire/ -- Aprea Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Scott Coiante as Senior Vice President and Chief Financial Officer.
  • An experienced finance executive in biotech, Mr. Coiante brings nearly 20 years of accounting, fundraising and operational experience to Aprea.
  • "We are thrilled to welcome Scott to the Aprea team," said Christian S. Schade, President and Chief Executive Officer of Aprea Therapeutics.
  • Scott Coiante joins Aprea from Agile Therapeutics, where he was Senior Vice President and Chief Financial Officer.

Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)

Retrieved on: 
Tuesday, April 16, 2019
Health, Articles, Food and Drug Administration, Life sciences, Fast track, Orphan drug, Breakthrough therapy

In addition, FDA has also granted Orphan Drug Designation to APR-246 for treatment of MDS.

Key Points: 
  • In addition, FDA has also granted Orphan Drug Designation to APR-246 for treatment of MDS.
  • "The granting of Fast Track designation and Orphan Drug Designation by FDA for APR-246 in TP53 mutated MDS underscores the significant unmet medical need in this disease," said Christian S. Schade, President and Chief Executive Officer of Aprea.
  • The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to address unmet medical needs.
  • A drug program with Fast Track status is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval.

Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta

Retrieved on: 
Wednesday, April 3, 2019
Medicine, Clinical medicine, Immune system, Medical specialties, Cancer treatments, Cancer immunotherapy, Checkpoint inhibitor, Immune checkpoint, Programmed cell death protein 1, Tumor microenvironment, Cancer, Chemotherapy

BOSTON and STOCKHOLM, April 3, 2019 /PRNewswire/ -- Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta.

Key Points: 
  • BOSTON and STOCKHOLM, April 3, 2019 /PRNewswire/ -- Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta.
  • The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in combination.
  • Also, the administration of APR-246 together with anti-PD-1 and anti-CTLA-4 dual immune checkpoint blockade significantly augmented anti-tumor control.
  • Additional Phase 1b/2 studies for APR-246 in MDS and AML are also underway and in planning together with other approved anti-cancer agents.

Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer

Retrieved on: 
Monday, March 25, 2019

BOSTON and STOCKHOLM, March 25, 2019 /PRNewswire/ --Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the appointment of Dr. Eyal C. Attar as Senior Vice President and Chief Medical Officer.

Key Points: 
  • BOSTON and STOCKHOLM, March 25, 2019 /PRNewswire/ --Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the appointment of Dr. Eyal C. Attar as Senior Vice President and Chief Medical Officer.
  • A trained physician in medical hematology and oncology, Dr. Attar brings nearly 20 years of medical research and clinical development experience to Aprea.
  • "I am thrilled to join the Aprea team at this exciting time in the company's evolution," said Dr. Attar.
  • Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead.

Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego

Retrieved on: 
Sunday, December 2, 2018
RTT, Cancer, Nucleosides, Lactams, Cell biology, Biology, Orphan drugs, Triazines, Acute myeloid leukemia, Azacitidine, P53, 7+3

BOSTON and STOCKHOLM, Dec. 2, 2018 /PRNewswire/ --Aprea Therapeutics presented results at the 2018 ASH Annual Meeting from its Phase Ib/II clinical study in MDS.

Key Points: 
  • BOSTON and STOCKHOLM, Dec. 2, 2018 /PRNewswire/ --Aprea Therapeutics presented results at the 2018 ASH Annual Meeting from its Phase Ib/II clinical study in MDS.
  • The ongoing study is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53 mutated MDS.
  • No dose-limiting toxicities have been experienced to date and no exacerbation of the expected AZA-related safety profile has been observed.
  • Eligible patients in the Phase Ib/II clinical study include HMA nave, TP53 mutated MDS and oligoblastic acute myeloid leukemia (AML, 30% blasts).

Aprea Therapeutics Closes EUR 50 Million Financing

Retrieved on: 
Friday, November 30, 2018
Tumor suppressor genes, Biology, Cell biology, Proteins, Transcription factors, Carcinogenesis, Tumor suppressor, P53, HealthCap, Genetics

A representative from Redmile Group will also be appointed as Director to the Aprea Therapeutics Board of Directors.

Key Points: 
  • A representative from Redmile Group will also be appointed as Director to the Aprea Therapeutics Board of Directors.
  • Proceeds from the financing will be used to advance the clinical development of APR-246, a first-in-class anticancer agent that reactivates mutated p53 tumor suppressor protein.
  • Aprea Therapeutics is a Boston, Massachusetts- and Stockholm, Sweden-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53.
  • In March 2016, Aprea completed a EUR 46 million Series B financing with an international syndicate co-led by Versant Ventures and 5AM Ventures, with additional participation by Sectoral Asset Management, HealthCap, acting as local lead investor, and existing investor, Karolinska Development.

Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm

Retrieved on: 
Sunday, June 17, 2018
Cancer, Cell biology, Biology, Proteins, RTT, Acute myeloid leukemia, Orphan drugs, Lactams, P53, Azacitidine, Minimal residual disease

BOSTON and STOCKHOLM, June 17, 2018 /PRNewswire/ --Aprea Therapeutics presented results at the 2018 EHA Annual Meeting from its Phase Ib/II clinical study in MDS.

Key Points: 
  • BOSTON and STOCKHOLM, June 17, 2018 /PRNewswire/ --Aprea Therapeutics presented results at the 2018 EHA Annual Meeting from its Phase Ib/II clinical study in MDS.
  • The ongoing study is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53 mutated MDS.
  • Relative to baseline, p53 immunohistochemistry scores, mutant TP53 variant allele frequency (VAF) and TP53 minimal residual disease (MRD) were significantly decreased at time of disease assessment.
  • Eligible patients in the Phase Ib/II clinical study include HMA nave, TP53 mutated MDS and oligoblastic acute myeloid leukemia (AML, 30% blasts).